Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer
A precision oncology company, Evexta Bio S.A., established by Truffle Capital, known for founding Abivax and Carvolix, revealed a clinical partnership and supply deal aimed at commencing a Phase 1b trial. The study will couple their primary investigational compound, rupitasertib, with Roche's investigational compound giredestrant, an SERD, focusing on treating ER+, HER2-, ESR1-m patients. This collaboration marks a significant step in the development of targeted therapies.